

1/35




FIG. 1A




FIG. 1B

2/35




FIG. 1C




FIG. 1D

3/35




FIG. 1E

4/35




FIG. 2A

5/35




FIG. 2B




FIG. 2C

6/35




FIG. 2D




FIG. 2E



FIG. 2F




FIG. 2G




FIG. 3A




FIG. 3B

9/35




FIG. 3C

Target	Peptide hits (MS)	RPKM (RNA-seq)	Fold-enrichment (microarray)
Glut1 (<i>Slc2a1</i>)	139	1095	134.5
TfR	105	923.5	15.6
Bsg	32	8135	14.3
CD98hc (<i>Slc3a2</i>)	57	615	2.5
Lrp1	0	1.8	1.2
InsR	0	31.2	1.0
Ldlrad3	0	54.4	5.2
CD320	0	67.5	8.6

FIG. 3D

10/35




FIG. 4A




FIG. 4B




FIG. 4C

11/35




FIG. 4D




FIG. 4E

12/35




FIG. 4F




FIG. 4G

13/35




FIG. 4H




FIG. 4I

14/35




FIG. 5A



FIG. 5B

15/35




FIG. 5C




FIG. 5D

16/35




FIG. 5E




FIG. 5F

17/35




FIG. 5G




FIG. 5H

18/35




FIG. 5I




FIG. 5J

19/35




FIG. 5K




FIG. 5L

20/35




Fig. 6

21/35





FIG. 6 continued

22/35

D



E




FIG. 6 continued

23/35




FIG. 6 continued




FIG. 6 continued

25/35




Fig. 6K

26/35




Fig. 6L




FIG. 6M

27/35




FIG. 6N





FIG. 6O

28/35

**FIG. 6P**








FIG. 7

30/35

C**D****FIG. 7 continued**

31/35

**F**

G






FIG. 7 continued

32/35

**Fig. 7 continued**

33/35





FIG. 7 continued

34/35

**FIG. 8**

Target antibody	Binding affinity (nM)
anti-Lrp1	1
anti-InsR	21
anti-Ldlrad3	7
anti-CD320	0.5
anti-Glut1	0.6
anti-Bsg ^A	13.5
anti-Bsg ^B	102
anti-CD98hc ^A	0.8
anti-CD98hc ^B	70.7

FIG. 9




FIG. 10